1. Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study. (5th December 2022) Authors: Howard, James; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; De Bleecker, Jan; Murai, Hiroyuki; Meisel, Andreas; Beydoun, Said; Pasnoor, Mamatha; Guglietta, Antonio; Ulrichts, Peter; T'joen, Caroline; Brauer, Edward; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato Journal: Neurology Issue: Volume 99:Number 23(2022)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study. (5th December 2022) Authors: Howard, James; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; De Bleecker, Jan; Murai, Hiroyuki; Meisel, Andreas; Beydoun, Said; Pasnoor, Mamatha; Guglietta, Antonio; Ulrichts, Peter; T'joen, Caroline; Brauer, Edward; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato Journal: Neurology Issue: Volume 99:Number 23(2022)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study. (5th December 2022) Authors: Howard, James; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; De Bleecker, Jan; Murai, Hiroyuki; Meisel, Andreas; Beydoun, Said; Pasnoor, Mamatha; Guglietta, Antonio; Ulrichts, Peter; T'joen, Caroline; Brauer, Edward; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato Journal: Neurology Issue: Volume 99:Number 23(2022)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study. (5th December 2022) Authors: Howard, James; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; De Bleecker, Jan; Murai, Hiroyuki; Meisel, Andreas; Beydoun, Said; Pasnoor, Mamatha; Guglietta, Antonio; Ulrichts, Peter; T'joen, Caroline; Brauer, Edward; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato Journal: Neurology Issue: Volume 99:Number 23(2022)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Issue 2 (10th December 2019) Authors: Newland, Adrian C.; Sánchez‐González, Blanca; Rejtő, László; Egyed, Miklos; Romanyuk, Nataliya; Godar, Marie; Verschueren, Katrien; Gandini, Domenica; Ulrichts, Peter; Beauchamp, Jon; Dreier, Torsten; Ward, E. Sally; Michel, Marc; Liebman, Howard A.; de Haard, Hans; Leupin, Nicolas; Kuter, David J. Journal: American journal of hematology Issue: Volume 95:Issue 2(2020:Feb.) Page Start: 178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. (4th June 2019) Authors: Howard, James F.; Bril, Vera; Burns, Ted M.; Mantegazza, Renato; Bilinska, Malgorzata; Szczudlik, Andrzej; Beydoun, Said; Garrido, Francisco Javier Rodriguez De Rivera; Piehl, Fredrik; Rottoli, Mariarosa; Van Damme, Philip; Vu, Tuan; Evoli, Amelia; Freimer, Miriam; Mozaffar, Tahseen; Ward, E. Sal... Journal: Neurology Issue: Volume 92:Number 23(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Issue 7 (July 2021) Authors: Howard, James F; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; Margania, Temur; Murai, Hiroyuki; Bilinska, Malgorzata; Shakarishvili, Roman; Smilowski, Marek; Guglietta, Antonio; Ulrichts, Peter; Vangeneugden, Tony; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato; De Bleeker, Jan;... Journal: Lancet neurology Issue: Volume 20:Issue 7(2021) Page Start: 526 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Issue 7 (July 2021) Authors: Howard, James F; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; Margania, Temur; Murai, Hiroyuki; Bilinska, Malgorzata; Shakarishvili, Roman; Smilowski, Marek; Guglietta, Antonio; Ulrichts, Peter; Vangeneugden, Tony; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato; De Bleecker, Jan... Journal: Lancet neurology Issue: Volume 20:Issue 7(2021) Page Start: 526 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗